Method to confer cell culture replication activity to different hepatitis c virus isolates
CA 2514918 C · Owner: Merck Sharp & Dohme Corp. · Inventors: Flores, Osvaldo; Grobler, Jay; Markel, Eric J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention features methods for producing HCV replicons using HCV encoding sequences from different isolates. The featured methods are based on the discovered importance of NS3 amino acid position 470 in conferring cell culture replication activity to different HCV isolates.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 9, 2004 and granted July 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 9, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 9, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.